Oncology Peer Review On-The-Go: Kami Maddocks, MD, on Rechallenging With Rituximab and Second-Line Therapies for R/R DLBCL

News
Podcast

CancerNetwork® speaks with Kami Maddocks, MD, in part 2 of a 3-part series on CD19–directed agents and other second-line agent for relapsed/refractory diffuse large B-cell lymphoma.

CancerNetwork® spoke with Kami Maddocks, MD, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University Wexner Medical Center, about CD19-directed agents, avoiding rechallenging with rituximab (Rituxan), and outcomes with second-line therapy for transplant-ineligible patients with diffuse large B-cell lymphoma.

Visit cancernetwork.com to check out the first episode of this 3-part series here.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Recent Videos
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content